Aktienanalyse zu MeiraGTx Holdings PLC (MGTX)MGTXMeiraGTx Holdings PLC

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

MeiraGTx Holdings PLC (MGTX) is a good buy right now due to its current price of $13.82, which is significantly below the analyst price targets of $26 and $30, indicating substantial upside potential. The company has recently secured up to $400 million in funding, enhancing its financial stability and growth prospects, as evidenced by a remarkable 538.46% earnings surprise in its last report with an EPS of 1.71. However, the main risk is the high forward P/E ratio of 67.57, which suggests that the stock may be overvalued if growth does not materialize as expected.

3 analysts cover MGTX: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 21.50.